Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioReliance Opens New U.S. Clearance Services Laboratories

Published: Thursday, September 12, 2013
Last Updated: Thursday, September 12, 2013
Bookmark and Share
Completes global facility upgrade plan.

Sigma-Aldrich® Corporation’s BioReliance® has opened a new Clearance Services facility in Rockville, MD.

This world-class facility, commissioned on August 1, 2013, allows BioReliance to offer increased capacity and flexible scheduling while maintaining its core focus on providing industry-leading quality, expertise and value.

The new U.S. facility more than doubles the amount of space available to clients to conduct their critical downstream bioprocessing studies.

Designed with input from clients and built to complement BioReliance’s global viral clearance services capabilities, the Rockville facility features four large clearance suites with modular layouts that allow for customized laboratory setups.

All studies performed at the facility are completely secure and supported by dedicated scientists and chromatography equipment, such as GE Healthcare’s ÄKTA® avant.

Every project is fully compliant with applicable global guidelines and regulations, including those from the U.S. Food and Drug Administration and European Medicines Agency.

Completed studies receive a consolidated report that includes comprehensive titration and/or process data. BioReliance has already successfully conducted several client studies and quality audits in the new facility.

“Combining our deep knowledge and proven experience with a global investment in modern facilities and equipment enables BioReliance to offer robust validation packages and proprietary CompleteClearance™ services to our clients. It’s all about simplifying the viral clearance process through an unrivaled combination of scientific expertise, client-focused service and decades of experience,” said Archie Cullen, president of BioReliance.

Cullen continued, “Any time a client comes to work with us, they are assured that their study is expertly designed and performed by personnel that have participated in thousands of successful studies in support of clinical and commercial biopharmaceutical products.”

Clients using BioReliance’s U.S. facility will have access to a wide range of resources, including personalized modular laboratory suites with spacious, technology-enabled lounges, unique “suite-to-lounge” monitoring, and support from industry-leading personnel.

The Rockville Clearance Services facility investment completes BioReliance’s upgrade to its global offering designed to deliver a total client solution and experience.

The Stirling, Scotland (U.K.), Clearance Services laboratories were completely renovated and expanded in 2011.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Chi-Med Initiates Sulfatinib Phase III Registration Study
Company has initiated SANET-p, a Phase III registration trial of sulfatinib with pancreatic neuroendocrine tumors (“NETs”).
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!